Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12617001119381
ACTRN12617001119381
Recruiting
未知

Circulating Tumour DNA as a Marker of Residual Disease and Response to Adjuvant Chemotherapy in Stage I - IV Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer (EOC)

Walter and Eliza Hall Institute of Medical Research0 sites100 target enrollmentJuly 31, 2017
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Walter and Eliza Hall Institute of Medical Research
Enrollment
100
Status
Recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 31, 2017
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Walter and Eliza Hall Institute of Medical Research

Eligibility Criteria

Inclusion Criteria

  • •1\. Patients that have had primary debulking surgery for curatively resected stage I\-IV high grade serous, endometrioid or clear cell carcinoma, or carcinosarcoma of the ovary, fallopian tube or primary peritoneum. Stage IV patients can only be included in the study if they have had a complete resection of all macroscopic disease with no residual disease.
  • •Patients commencing neoadjuvant chemotherapy for stage I\-
  • •III high grade serous, endometrioid or clear cell carcinoma, or carcinosarcoma of the ovary, fallopian tube or primary peritoneum. Women must be planned to undergo interim debulking surgery.
  • •2\. A representative tumour sample can be made available for molecular testing after surgery or a core biopsy pre neoadjuvant chemotherapy if available.
  • •3\. Fit and planned for adjuvant chemotherapy.

Exclusion Criteria

  • •1\. History of another primary cancer within the last 3 years,
  • •with the exception of non\-melanomatous skin cancer,
  • •carcinoma in situ of the cervix and fully resected stage1a
  • •endometrial cancer
  • •2\. Patients with EOC of mucinous subtype and sarcoma
  • •3\. Patients with Stage IV disease who have residual disease
  • •4\. Patients \<18 years

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Circulating Tumour DNA as a Marker of Complete Pathological Response and Long Term Outcome for Locally Advanced Rectal Cancer Treated with Pre-operative Chemoradiotherapy
ACTRN12612000327886udwig Institute for Cancer Research320
Active, not recruiting
Not Applicable
Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian CancerOvarian Cancer
NCT03691012Walter and Eliza Hall Institute of Medical Research118
Recruiting
Not Applicable
Circulating tumor DNA as a noninvasive biomarker in patients with thyroid cancerC73Malignant neoplasm of thyroid gland
DRKS00022441niversitätsklinikum Freiburg75
Recruiting
Not Applicable
Circulating tumor DNA as a noninvasive biomarker in patients with Non-Hodgkin Lymphoma (NHL)C83.3C85Diffuse large B-cell lymphomaOther and unspecified types of non-Hodgkin lymphoma
DRKS00024180niversitätsklinikum Freiburg200
Not yet recruiting
Not Applicable
Circulating tumor DNA as biomarker for perihilar cholangiocarcinomaPerihilar cholangiocarcinoma/ Perihilair cholangiocarcinoomKlatskin-tumorBiomarkerCirculating tumor DNA /Circulerend tumor DNA (ctDNA)
NL-OMON27478AMC20